Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JK500
- Development stage
- Phase 1
- Lead developer
- Institute of Hematology and Blood Diseases Hospital
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Stem Cell Therapies → Cell Therapies, Other Cell Types → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
JK500 is a regenerative cell therapy product composed of natural killer (NK) cells derived from human embryonic stem cells, suspended in 0.9% sodium chloride solution. It is being developed as an investigational treatment for relapsed or refractory pediatric acute myeloid leukemia (AML). The therapy aims to leverage the cytotoxic activity of NK cells to target and eliminate malignant hematopoietic cells in patients with AML. The drug is currently under early phase 1 clinical investigation, primarily at the Hematology Hospital of Chinese Academy of Medical Sciences[1][2][6].
- Brand names
- JK500JK-500JK 500
- Other names
- JK500 cell injectionJK-500 cell injectionJK 500 cell injection
02
Targets
NKG2DL (NKG2D ligand family)
Beyond the preview
Go deeper on JK500.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JK500.